Potent and selective IKKβ
= 37 nM). Displays selectivity over 85 other kinases. Inhibits IL-1β
production in a steroid-insensitive in vitro
model of oxidative stress.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Novel tight-binding inhibitory factor-κB kinase (IKK-2) inhibitors demostrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Sommers et al.
The citations listed below are publications that use Tocris products. Selected citations for PF 184 include:
Showing Results 1 - 1 of 1